Conferences EASL 2014
Other Infections
Studies Shed Light on Hepatitis C Virus Sexual Transmission among Gay Men
- Details
- Category: HCV Sexual Transmission
- Published on Tuesday, 20 May 2014 00:00
- Written by Liz Highleyman
Hepatitis C virus (HCV) transmission among HIV positive gay men has leveled off in Amsterdam -- one of the first cities with an outbreak of apparently sexually transmitted HCV infection -- and it continues to be rare among HIV negative men who have sex with men, according to recent studies. Other research looked at HCV sexual transmission among HIV positive and negative men in Switzerland, and at the association between HCV viral load in blood and semen.
DDW 2014 and EASL 2014: Rifaximin May Be Beneficial for People with Advanced Liver Cirrhosis
- Details
- Category: Liver Decompensation
- Published on Sunday, 18 May 2014 00:00
- Written by Liz Highleyman
The antibiotic rifaximin may help prevent or improve hepatic encephalopathy and bleeding varices in people with decompensated liver disease, according to studies presented at the recent EASL International Liver Congress and Digestive Disease Week.
EASL 2014: Sofosbuvir + Ribavirin Is Safe and Effective for HCV Recurrence after Liver Transplant
- Details
- Category: HCV Treatment
- Published on Friday, 02 May 2014 00:00
- Written by Liz Highleyman
An interferon-free combination of sofosbuvir (Sovaldi) plus ribavirin taken for up to 24 weeks led to sustained virological response in 70% of liver transplant recipients with hepatitis C virus (HCV) recurrence, according to a poster presented at the 49thEASL International Liver Congress (EASL 2014) held recently in London.
CROI 2014 & EASL 2014: Treating Hepatitis B and C in HIV+ People Reduces Liver Disease
- Details
- Category: HCV Treatment
- Published on Monday, 12 May 2014 00:00
- Written by Liz Highleyman
Effective antiviral treatment that suppresses hepatitis B virus (HBV) repliaction or eradicates hepatitis C virus (HCV) can lower the risk of developing advanced liver disease including cirrhosis, hepatocellular carcinoma, and decompensation in people with HIV and viral hepatitis coinfection, according to studies presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI) and EASL International Liver Congress.
EASL 2014: VX-135 + Daclatasvir Shows Modest Cure Rate in Phase 2 Study
- Details
- Category: HCV Treatment
- Published on Friday, 02 May 2014 00:00
- Written by Liz Highleyman
Treatment with an interferon-free regimen of daclatasvir plus VX-135 for 12 weeks was safe and well-tolerated for genotype 1 chronic hepatitis C patients, but the sustained virological response rate of 83% for easier-to-treat patients did not stand up well to cure rates of 90% or higher seen with other similar combinations, according to a late-breaker poster presented at the 49thEASL International Liver Congress held recently in London.
EASL 2014: Idenix Hepatitis C Drugs Look Promising in Early Studies
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 06 May 2014 00:00
- Written by HIVandHepatitis.com
Idenix Pharmaceuticals' hepatitis C virus NS5A inhibitor samatasvir (formerly IDX179) plus Janssen's HCV protease inhibitor simeprevir (Olysio) and ribavirin produced early sustained virological response rates of about 80% in a small study presented at the 49th EASL International Liver Congress last month in London. Another study showed that the company's HCV polymerase inhibitor candidate IDX21437 looks good in preclinical studies and is a potential once-daily partner for samatasvir in interferon-free regimens.
EASL 2014: Sustained Response to Treatment Reduces Fatigue in Hepatitis C Patients
- Details
- Category: HCV Treatment
- Published on Tuesday, 29 April 2014 00:00
- Written by Liz Highleyman
Curative treatment that eliminates hepatitis C virus (HCV) from the body can reduce central fatigue, one of the most problematic symptoms associated with chronic hepatitis C, according to research presented at the EASL Liver International Liver Congressthis month in London.
EASL 2014: Long-term Tenofovir Maintains Viral Suppression in People with Hepatitis B
- Details
- Category: HBV Treatment
- Published on Friday, 02 May 2014 00:00
- Written by Liz Highleyman
Treatment with tenofovir (Viread) for 3 years remained effective in keeping hepatitis B virus (HBV) suppressed, normalizing liver inflammation, and potentially reducing liver disease progression, according to studies from Germany, France, and Spain presented at the 49thEASL International Liver Congress (EASL 2014) recently held in London.
EASL 2014: Sofosbuvir + Ribavirin for 24 Weeks Is Highly Effective Against HCV Genotype 4
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 29 April 2014 00:00
- Written by Liz Highleyman
A 24-week regimen of sofosbuvir (Sovaldi) plus ribavirin cured 93% of people with hard-to-treat hepatitis C virus (HCV) genotype 4, though treatment for only 12 weeks was not as effective, according to a poster presentation at the EASL International Liver Congress this month in London.
More Articles...
- EASL 2014: Sci-B-Vac Bests Engerix-B for Preventing Mother-to-Child HBV Transmission
- EASL 2014: Kaiser Study Examines Who Receives Hepatitis C Treatment
- EASL 2014: Researchers Look at Treatment as Prevention for Hepatitis C
- EASL 2014: Sofosbuvir Works Well Despite Multiple Negative Predictive Factors
- AbbVie Combination Safe and Highly Effective in Patients with Post-Transplant HCV Recurrence
- EASL 2014: Prolonged Pegylated Interferon + Tenofovir Does Not Prevent Hepatitis Delta Relapse
- EASL 2014: Sofosbuvir + GS-5816 NS5A Inhibitor Is Effective Against HCV Genotypes 1-6
- EASL 2014: Obeticholic Acid Looks Promising for Primary Biliary Cirrhosis, May Improve Gut Health
- EASL 2014: MK-5172 + MK-8742 Demonstrate Good Early Post-Treatment Response Rates
- EASL 2014: AbbVie 2-Drug Combo + Ribavirin Cures 100% of Previously Untreated HCV Genotype 4
- EASL 2014: BMS Dual Combo Cures 90% of Genotype 1b Hepatitis C in 24 Weeks
- EASL 2014: Sofosbuvir + Ribavirin Safe and Effective for Hepatitis C Patients with Advanced Liver Disease
- EASL 2014: Adding Interferon to Antivirals May Improve Response for Hepatitis B Patients
- EASL 2014: Chinese Herbal Compound Inhibits Hepatitis C Virus Replication
- EASL 2014: New Research Sheds Light on Liver Cancer Diagnosis, Staging, and Treatment
- EASL 2014: AbbVie 3-drug Combination Cures Up to 96% of Hepatitis C Patients with Cirrhosis
- EASL 2014: Sofosbuvir + Simeprevir Shows High Cure Rates for Hep C Patients with or without Cirrhosis
- Coverage of the 2014 EASL International Liver Congress
- Coverage of the 2014 EASL International Liver Congress
- EASL 2014: European Liver Specialists Recommend Use of Newest Hepatitis C Drugs
- EASL 2014: Sofosbuvir + Ledipasvir Cures More than 90% of First-time and Retreated Genotype 1 Patients
- EASL 2014: AbbVie Oral Regimen Cures 96% of Treatment-experienced Genotype 1 Patients
- EASL 2014: Sofosbuvir + Ledipasvir Is Safe and Effective for Relapsers and Hard-to-Treat Hep C Patients
- EASL 2014: 88% of Previous Relapsers Cured with Simeprevir Triple Therapy
- EASL 2014: Fatty Liver Disease Is a Risk Factor for Heart Disease and Diabetes
- EASL 2014: Sofosbuvir + Ledipasvir Produces Early Cure for 100% of HIV/HCV Coinfected Patients
- EASL 2014: WHO Recommends Global Use of Newest Hepatitis C Drugs, Urges Price Reductions
- EASL 2014: International Liver Congress Starts this Week in London
Web Design and Development by